Auranofin
Auranofin
CLINICAL USE
Active progressive rheumatoid arthritis in adults when NSAIDs inadequate alone
DOSE IN NORMAL RENAL FUNCTION
6 mg daily (maximum 9 mg in 3 divided doses)
PHARMACOKINETICS
Molecular weight                           :678.5 %Protein binding                           :60 %Excreted unchanged in urine     : 9–17 (approx 60% of absorbed gold) Volume of distribution (L/kg)       :No datahalf-life – normal/ESRD (hrs)      :26 days/ – DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : 3–6 mg daily 10 to 20     : 3 mg daily <10           : Avoid DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min HD                     :Not dialysed. Dose as in GFR <10 mL/minHDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/minCAV/VVHD      :Not dialysed. Dose as in GFR=10–20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
Take with or after food Start initially with morning and evening dose; if well tolerated, can take dose once a day OTHER INFORMATION
Warn patients to tell the doctor immediately if any of the following develop: sore throat, mouth ulcers, bruising, fever, malaise, rash, diarrhoea or non-specific illnessBlood tests should be carried out monthly, and treatment should be withdrawn if the platelets fall below 100 000/mm3, or if signs and symptoms suggestive of thrombocytopenia appearGold can produce nephrotic syndrome or less severe glomerular disease with proteinuria and haematuria, which are usually mild and transient. If persistent or clinically significant proteinuria develops, treatment with gold should be discontinued. Minor transient changes in renal function may also occurUrine tests should be carried out monthly to test for proteinuria and haematuria
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home